STEMCELL-TECHNOLOGIES
18.8.2021 12:02:03 CEST | Business Wire | Press release
STEMCELL Technologies and Hubrecht Organoid Technology (HUB) have announced that they have signed an agreement for the use of tissue-derived organoids—including lung, intestinal, and liver organoids—for use in preclinical toxicology screening and non-cancer drug development services to be offered by the Contract Assay Services division of STEMCELL. These services will help researchers and organizations working on drug development incorporate organoids into their preclinical testing programs and bring new therapeutics to market faster and more cost-effectively.
HUB Organoids™ are experimental models derived from the adult stem cells present in epithelial tissues. Expansion and differentiation of these stem cells gives rise to functional “mini-organs in a dish”. HUB Organoids™ represent a patient-specific way of assessing the efficacy and toxicity of drugs during preclinical screening. By closely mimicking human biology, HUB Organoids™ can be used to more accurately predict patient response to treatment than traditionally used systems. As such, they have the potential to drastically lower the costs and failure rates currently associated with bringing new treatments to market. Under the existing agreement, STEMCELL develops and supplies a wide range of cell culture kits that efficiently expand and maintain the different stem cell-derived organoids that will be used for many of these screening programs.
This new agreement complements HUB and STEMCELL’s existing partnership, where STEMCELL is the exclusive provider of cell culture media for all HUB Organoids™, by allowing STEMCELL to perform preclinical toxicology screening as well as non-cancer drug testing and validation services. "We are extremely pleased to be able to expand our partnership with HUB to include these new services," remarked Dr. Allen Eaves, STEMCELL’s Founder, President, and CEO. "As Scientists Helping Scientists, our goal is to make these incredible technologies more accessible to researchers, whether they are growing organoids in their own labs or partnering with service providers to advance their science."
“At HUB we are on a mission to bridge the gap between the lab and the clinic and bring patients-specific models into the lab,” said Dr. Robert Vries, HUB CEO. “Carefully selecting our strategic partners is key to expanding global access to HUB Organoid Technology and, ultimately, to improving patient care. STEMCELL has already demonstrated thought leadership in the Organoid Technology field; therefore, we believe that expanding the scope of our partnership to include services will benefit the research and drug development community worldwide.”
About STEMCELL Technologies
As Scientists Helping Scientists, STEMCELL Technologies is committed to providing high-quality cell culture media, cell isolation products, accessory reagents and services for life science research. Driven by science and a passion for quality, STEMCELL Technologies offers over 2500 products designed to support the basic to translational research continuum. Visit www.stemcell.com to learn more.
About HUB
Hubrecht Organoid Technology (HUB) was founded by the Hubrecht Institute, the University Medical Center Utrecht, and the Royal Netherlands Academy of Arts and Sciences (KNAW) to refine organoid development and foster organoid adoption globally. HUB Organoid Technology represents a paradigm-shift that bridges the gap between the lab and the clinic and effectively brings “patients in the lab” for drug discovery and development, preclinical patient stratification, predictive biomarker discovery, personalized medicine, clinical trials, regenerative medicine, and companion diagnostics applications. Learn more by visiting www.huborganoids.nl
View source version on businesswire.com: https://www.businesswire.com/news/home/20210818005144/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
a2z Radiology AI Receives EU MDR Certification for AI That Detects 182 Findings Across Head, Chest, Abdomen and Pelvis CT12.11.2026 09:00:00 CET | Press release
a2z-Drafter is the first AI product certified under the EU Medical Device Regulation to support both detection and report drafting across head, chest, abdomen and pelvis CT. a2z Radiology AI Inc. today announced that a2z-Drafter has been certified under the EU Medical Device Regulation (MDR). The software supports triage, detection and report drafting on CT scans of the head, chest, abdomen and/or pelvis. “Radiology teams have had to piece together separate AI tools for each condition and body region,” said Samir Rajpurkar, co-founder and CEO of a2z Radiology AI. “a2z-Drafter is one product that works on head, chest and abdomen-pelvis CT scans and gives the radiologist a structured starting point for the report. This certification lets us bring that to radiology teams in the European Union.” a2z-Drafter detects 182 validated radiological findings on CT studies of the head, chest, abdomen and/or pelvis, with supplementary attributes for selected findings. The findings span acute conditi
KiddeFenwal Secures A2P System Certification from Centre National de Prévention et de Protection in France12.11.2026 09:00:00 CET | Press release
Assurance Prévention Protection benchmark from CNPP marks key milestone in the global adoption of NATURA™ inert gas fire suppression system.Certification elevates proven technology that conserves water while safeguarding assets and minimizing downtime. KiddeFenwal, the global leader in fire protection and safety controls, has received an Assurance Prévention Protection (A2P) System Certification for its NATURA™ inert gas fire suppression system. The designation from France’s Centre National de Prévention et de Protection (CNPP), one of the most respected fire safety testing and certification organizations in Europe, illustrates how KiddeFenwal is expanding the reach of its industry-leading technologies throughout the world with the support of independent, third-party evaluators. “KiddeFenwal is grateful to CNPP for standing behind our proven NATURA™ system,” said Rekha Agrawal, CEO of KiddeFenwal. “The certification enables our systems to protect the facilities and institutions that ma
Shahrukhz Residences by Danube: Exclusive Gauri Khan-Designed Penthouses Worth USD 5.35 Million Each Sell Out on Launch Day12.11.2026 08:30:00 CET | Press release
Danube Properties unveiled Shahrukhz Residences by Danube, its fully furnished waterfront development in Dubai Maritime City, at a grand launch event on November 11 at Coca-Cola Arena, Dubai, in presence of the Danube Group Founder and Chairman Rizwan Sajan, Shah Rukh Khan and Gauri Khan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111982153/en/ Shahrukhz Residences by Danube: Exclusive Gauri Khan-Designed Penthouses Worth USD 5.35 Million Each Sell Out on Launch Day (Photo: AETOSWire) Hosted by filmmaker Karan Johar, the event marked the second collaboration between Rizwan Sajan and SRK. A highlight of the evening was the announcement that all Gauri Khan-designed penthouses, each valued at USD 5.35 Million, had sold out on launch day. Expressing gratitude for the phenomenal response, Rizwan Sajan said, “Shahrukhz Residences is more than a development; it represents our ambition to create homes that bring together exce
Allianz Delivers Record Nine-month Result of 14.1 Billion Euros and Raises 2026 Outlook12.11.2026 07:06:00 CET | Press release
3Q 2026 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111915059/en/ Oliver Bäte, Chief Executive Officer of Allianz SE Total business volume at 44.4 billion euros, an internal growth of 3.0 percent1. Excellent contribution from Asset Management and good internal growth in Property-Casualty. Operating profit rises 6.2 percent to 4.7 billion euros, driven by an outstanding result from the Asset Management segment, attributable to higher business volume and margins, and a strong contribution from Life/Health. Shareholders’ core net income increases 1.2 percent to 2.9 billion euros. Adjusted for offsetting measures following the sale of the stake in our Indian JVs, underlying growth is 3 percent. 9M 2026 Total business volume at 143.0 billion euros, an internal growth of 3.8 percent 1 , driven by excellent growth in Asset Management and good internal growth in Property-Casualty. Operating profit rises 7.8 percent to 14.1 bil
LTM Brings AI-Powered Quantum Error Mitigation to IBM Quantum Functions Catalog12.11.2026 06:30:00 CET | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today announced that AI-QEM, its proprietary AI-powered Quantum Error Mitigation capability, is now available in the IBM Quantum Functions Catalog. With this milestone, LTM becomes the first Global Systems Integrator (GSI) worldwide to publish a function in the catalog. The IBM Quantum Functions Catalog is an ecosystem of partner-built quantum software services that simplify quantum workflows and enable researchers and enterprises to run quantum experiments more efficiently for algorithm development and application prototyping. AI-QEM is available as a circuit function, allowing users of eligible IBM Quantum access plans to apply LTM's error mitigation capability directly within their Qiskit workflows. Quantum computers are inherently susceptible to noise and errors that can impact computational outcomes. While conventional error mitigation techniques often require additional circuit executions, quantum processing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom